Psychedelic Stock Gainers And Losers From December 9, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.78% at $1.11 Numinus Wellness (OTC:NUMIF) shares closed up 1.88% at…
‘Congress Pushes Military To Consider Psychedelics And Marijuana Therapy, While Other Cannabis Provisions Left Out Of Defense Bill’ – MarijuanaMoment
https://www.marijuanamoment.net/congress-pushes-militar
‘DEA Proposes Even Higher 2023 Production Quotas For Psychedelics Like MDMA And Psilocyn: “DEA is committed to ensuring an adequate and uninterrupted supply of controlled substances.”‘ – Marijuana Moment
https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
Psychedelic Stock Gainers And Losers From November 23, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 54.13% at $0.13 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 8.56%…
Psyched: Musk’s Empathy Tweets, Psychedelics In Congress, Oregon’s Opt-Outs, MAPS’ MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets
Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period.
Cybin Provides Progress Update On Its CYB004-E Phase 1 Trial
Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1